Jason Lettmann - ALXO / ALX Oncology Holdings Inc. - Insider Trade Report

Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Jason Lettmann in ALXO / ALX Oncology Holdings Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2025-09-17	71,163	1.0805	71,163	1.0805	76,892	5	1.2700	13,486	17.54
2025-09-16	21,070	1.0660	21,070	1.0660	22,461
2024-03-14	4,400	11.3117	4,400	11.3117	49,771

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Jason Lettmann in ALXO / ALX Oncology Holdings Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2025-08-15	2,382	0.6404	2,382	0.6404	1,525	0	0.6443	10	0.64
2025-02-19	2,159	1.1502	2,159	1.1502	2,483
2021-12-13	286,496	27.4900	286,496	27.4900	7,875,775

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Transaction History